Consensus $6.22B. The company said, “Organon (OGN) does not provide GAAP financial measures on a forward-looking basis because the company cannot predict with reasonable certainty and without unreasonable effort, the ultimate outcome of legal proceedings, unusual gains and losses, the occurrence of matters creating GAAP tax impacts, and acquisition-related expenses. These items are uncertain, depend on various factors, and could be material to Organon’s results computed in accordance with GAAP.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN:
- Organon announces American Academy of Dermatology recommendation for Vtama cream
- Morning Movers: Tesla higher following Q2 delivery figures
- Organon ELENA trial misses primary endpoint, to discontinue OG-6219 program
- OGN Lawsuit Alert! Class Action Lawsuit Against Organon & Co.
- Organon Concludes Annual Meeting with Key Decisions